The coexistence of chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea syndrome in a single patient is known as “overlap syndrome,” and worsens the prognosis of the affected subjects. A marked bronchodilation may be useful for the treatment of this condition. In fact, as stated in the GOLD 2017 guidelines, the combination of indacaterol/glycopyrronium may exert positive synergistic effects on smooth muscle cell and airway resistance, with a more pronounced efficiency in reducing lung hyperinflation. Noteworthy, inhaled bronchodilators favorably alter the dynamically determined components of resting lung hyperinflation and help deflate the overinflated lungs. This is particularly important in order to improve dyspnea, exercise performance, and night saturation, especially when combined with continuous positive airway pressure ventilation, as reported in our case series. We report 3 cases of patients with COPD in a stable clinical condition, referred to the Department of Respiratory Pathophysiology at the “Mariano Santo” Hospital in Cosenza, due to possible symptoms suggestive of obstructive sleep apnea, and who were successfully treated with indacaterol/glycopyrronium at a fixed dose.

Chronic obstructive pulmonary disease (COPD) is currently the fourth leading cause of death in the world, projected to reach the third podium position by 2020. More than 3 million people have died from COPD, accounting for 6% of all deaths globally [1]. Obstructive sleep apnea (OSA) syndrome is a common disease that involves at least 4% of males and 2% of the female adult population. OSA is probably the most common respiratory disorder, with recent data from the United States and Europe reporting a rate between 14 and 49% of middle-aged men suffering from clinically relevant OSA [2, 3]. On an individual level, OSA leads to a significant decrease in quality of life and functional capacity, alongside a markedly increased risk of cardiovascular diseases and death [2, 3]. A bulk of data also suggest that the presence and severity of OSA and associated nocturnal hypoxemia correlate with an increased risk of diabetes and cancer. OSA is characterized by recurrent episodes of upper airway obstruction during sleep, corresponding to recurrent cycles of desaturation and re-oxygenation, sympathetic overactivity, and intrathoracic pressure changes. All these features lead to sleep fragmentation and consequent daytime fatigue and sleepiness [4]. COPD and OSA syndrome represent 2 of the most prevalent chronic respiratory disorders in clinical practice, and their coexistence in the same patients is referred to as “overlap syndrome” [5].

Epidemiological studies indicate a prevalence of the overlap syndrome of approximately 1% in the population. In the Sleep Heart Health Study, a large community-based cohort study which included polysomnography and spirometry, 0.5% of the participants presented airflow obstruction. In a European study with predominantly mild COPD patients, OSA recurred in 3% [5, 6].

Nocturnal hypoxemia is one of the most important sleep abnormalities in COPD and OSA. The overlap syndrome causes more severe nocturnal hypoxemia than either disease alone [6, 7]. Daytime hypercapnia is also more common in overlap patients. Noteworthy, the more pronounced hypoxemia and hypercapnia might result in greater cardiovascular morbidity and mortality, as some evidence reported. Pulmonary hypertension is more prevalent in overlap patients, and a preliminary report indicates that overlap patients also suffer from higher mortality rates than patients with COPD alone [3, 7].

Inhaled bronchodilators are the main therapeutic agents for COPD. New agents such as indacaterol and glycopyrronium, with a prolonged duration of effects of up to 24 h, have recently been developed, providing new perspectives in the field of the once-a-day therapy in fixed combinations. Multiple evidence supports the mechanistic rationale, clinical efficacy, and safety of combining anticholinergic and β2-agonist bronchodilators [8, 9]. The rationale of using these classes of drugs is based on the high density of β2-adrenergic receptors available throughout the respiratory tree and on the key pathogenic role played by neurogenic cholinergic mechanisms in COPD.

The pharmacological characterization of the interaction between glycopyrronium bromide and indacaterol fumarate has shown that the coadministration of these two bronchodilators leads to a synergistic improvement of bronchodilation. Thus, by leveraging different receptor types at submaximal doses, this combination increases the therapeutic benefits while minimizing the dose-dependent side effects [10, 11].

We report 3 cases of patients with COPD in a stable clinical condition, referred to the Department of Respiratory Pathophysiology at the “Mariano Santo” Hospital in Cosenza, due to possible symptoms suggestive of OSA, and who were successfully treated with indacaterol and glycopyrronium at a fixed dose.

Three patients complaining of symptoms suggestive of OSA came to our attention. These symptoms were unexplained daytime sleepiness, restless sleep, loud snoring, morning headaches, difficulties in concentrating, mood changes (irritability, anxiety, and depression), forgetfulness, increased urination and/or nocturia, and dyspnea on exertion. For all patients, the diagnosis of GOLD 2, B COPD dated 2 years and was indicated by another hospital, whose pneumonologists suggested starting long-acting muscarinic antagonist (LAMA) therapy with glycopyrronium.

A detailed clinical history was obtained and a physical examination was performed. Lung function testing consisted of spirometry, carried out according to the American Thoracic Society (ATS) guidelines; exercise tolerance was assessed with the six-minute walking test and modified Medical Research Council (mMRC) dyspnea scale. All patients and control subjects underwent a full-night cardiorespiratory study (Vitalnight, Vitalaire – Airliquide Healthcare); thoracoabdominal movements were detected by inductance plethysmography, arterial oxygen saturation (SaO2) was measured by a finger probe oximeter, and nasal flow was measured by nasal cannulas and pressure transducer. Respiratory events were manually scored. Additionally, subjective somnolence was evaluated in all participants by the Epworth Sleepiness Scale (ESS). Morning arterial blood gas concentrations were determined (ABL 520, Radiometer, Copenhagen), and a standard spirometry was performed. The ratio between the forced expiratory volume in the first second and the forced vital capacity (FEV1/FVC) was considered indicative of airway obstruction if < 70% (Table 1). All patients were diagnosed with OSA syndrome and referred to continuous positive airway pressure therapy and daily oxygen therapy.

Table 1.

Baseline characteristics of the 3 patients with overlap syndrome in our case series

Baseline characteristics of the 3 patients with overlap syndrome in our case series
Baseline characteristics of the 3 patients with overlap syndrome in our case series

Four months after treatment initiation, patients’ compliance was objectively measured with a machine time counter. Moreover, all patients were re-administered the ESS questionnaire and their respiratory function was re-evaluated. A second full-night cardiorespiratory study was performed during ventilation therapy.

Polysomnographic data showed an improvement of lung function at night, although nocturnal desaturation analyses were still prolonged (see Table 2 for details).

Table 2.

Clinical features of the 3 patients after the initiation of continuous positive airway pressure ventilation (CPAP) and after the addition of indacaterol/glycopyrronium (I/G) combination therapy to their therapeutic management strategy

Clinical features of the 3 patients after the initiation of continuous positive airway pressure ventilation (CPAP) and after the addition of indacaterol/glycopyrronium (I/G) combination therapy to their therapeutic management strategy
Clinical features of the 3 patients after the initiation of continuous positive airway pressure ventilation (CPAP) and after the addition of indacaterol/glycopyrronium (I/G) combination therapy to their therapeutic management strategy

All patients indicated remarkable improvements from their subjective perspective of daytime and nighttime symptoms, including night snoring, daytime sleepiness, nocturia, concentration, and mood changes. Conversely, dyspnea on exertion still persisted, as demonstrated also from the improvement in meters walked at the walking test (Table 2). A repeat spirometry indicated persisting pulmonary obstruction, with an increased Motley index (residual volume to total lung capacity ratio, %), expressing dynamic hyperinflation [12].

The recent GOLD 2017 guidelines suggest treating COPD patients with persisting airflow limitation with the long-acting β2-agonist (LABA) plus LAMA combination, especially in cases where a single long-acting bronchodilator (LABA or LAMA) did not provide adequate control of respiratory symptoms. Thus, we switched our patients to the indacaterol/glycopyrronium combination therapy [13]. Three months after therapy modification, our patients were re-evaluated for lung function by means of spirometry, walking test, and mMRC dyspnea scale. Overnight respiratory function was also checked by nocturnal pulse oximetry testing during continuous positive airway pressure ventilation without oxygen addition. The results showed improvements in the Motley index (reducing air trapping), walking test, and mMRC dyspnea scale (Table 2). Thus, therapy was confirmed with further suspension of oxygen administration during the ventilator support.

Synergistic effects of indacaterol and glycopyrronium are responsible for their dual action, based on reciprocal potentiation resulting in a maximization of bronchodilation [14]. Laboratory studies suggest that synergistic effects may occur between LABA and LAMA by a variety of mechanisms. For example, β2-adrenoceptor agonists can activate prejunctional β2-adrenoceptors to reduce acetylcholine release, and inhibitory crosstalk may exist between M3 receptors and β2-adrenoceptors in airway smooth muscle cells. Bronchodilators reduce airway smooth muscle tone and resistance, improve airflow, and accelerate the mechanical time constants for lung emptying [14, 15]. In this way, inhaled bronchodilators favorably alter the dynamically determined components of resting lung hyperinflation and help deflate the overinflated lungs. Moreover, the combination of LAMA and LABA can have additive effects on reducing lung hyperinflation [10, 15].

The Sleep Heart Health Study demonstrated that patients with both OSA and COPD are at a greater risk of prolonged oxygen desaturation at night than patients with only OSA; this more prolonged hypoxemia, or even the coexistence of COPD, appears to considerably increase morbidity and mortality, as compared to OSA alone. There is also increasing evidence that both COPD and OSA may have systemic consequences [16, 17]. Both conditions cause inflammation via various mediators (tumor necrosis factor alpha, interleukin-6, and interleukin-8), in addition to the oxidative stress they create [16]. An excellent review by McNicholas [3] highlights the similar mechanisms through which these diseases may lead to cardiovascular comorbidities [18].

Our aim in presenting this case series was to highlight the complexity of treating patients with overlap syndrome, in which the focus on symptoms and pulmonary functional parameters both at daytime and at night can prevent improper and costly therapy. In our report, we maximized bronchodilation with the association indacaterol/glycopyrronium, thus resolving persistent hyperinflation and being able to stop oxygen administration. Effective and sustained bronchodilation is a key strategy for improving dyspnea and exercise performance, and it can also improve nocturnal respiratory capabilities by improving night saturation.

Our limited clinical experience should be regarded with interest in the light of new clinical randomized controlled studies, in order to improve our knowledge of the overlap syndrome and thus allowing clinicians to find the right balance between ventilation and bronchodilator therapy in these patients.

The authors thank Luca Giacomelli, PhD, for providing medical writing on behalf of Content Ed Net; this assistance was funded by Novartis Farma SpA.

The authors have no conflicts of interest directly relevant to this paper.

1.
Vestbo J, Hurd SS, Agusti AG, et al: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347–365.
2.
Epstein L, Kristo D, Strollo PJ Jr, Friedman N, Malhotra A, Patil SP, et al; Adult Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine: Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med 2009; 5: 263–276.
3.
McNicholas WT: Chronic obstructive pulmonary disease and obstructive sleep apnea: overlaps in pathophysiology, systemic inflammation, and cardiovascular disease. Am J Respir Crit Care Med 2009; 180: 692–700.
4.
Weitzenblum E, Chaouat AR, Kessler R, Canuet M: Overlap syndrome: obstructive sleep apnea in patients with chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5: 237–241.
5.
Mieczkowski B, Ezzie ME: Update on obstructive sleep apnea and its relation to COPD. Int J Chron Obstruct Pulmon Dis 2014; 9: 349–362.
6.
Lee R, McNicholas WT: Obstructive sleep apnea in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 2011; 17: 79–83.
7.
Marrone O, Salvaggio A, Insalaco G: Respiratory disorders during sleep in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2006; 1: 363–372.
8.
Cazzola M, Page CP, Calzetta L, Matera MG: Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012; 64: 450–504.
9.
Vogelmeier C, Banerji D: NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease. Ther Adv Respir Dis 2011; 5: 163–173.
10.
O’Donnell DE, Casaburi R, Vincken W, Puen<X00_Del_TrennDivis>--</X00_Del_TrennDivis> te-Maestu L, Swales J, Lawrence D, Kramer B; INABLE 1 study group: Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med 2011; 105: 1030–1036.
11.
Rossi A, Centanni S, Cerveri I, Gulotta C, Foresi A, Cazzola M, Brusasco V: Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. Respir Med 2012; 106: 84–90.
12.
O’Donnell DE, Webb KA, Neder JA: Lung hyperinflation in COPD: applying physiology to clinical practice. COPD Res Pract 2015; 1: 4.
13.
Sykes DA, Dowling MR, Leighton-Davies J, Kent TC, Fawcett L, Renard E, Trifilieff A, Charlton SJ: The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J Pharmacol Exp Ther 2012; 343: 520–528.
14.
Cohen JS, Miles MC, Donohue JF, Ohar JA: Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA. Int J Chron Obstruct Pulmon Dis 2016; 11: 785–797.
15.
Mahler DA, Decramer M, D’Urzo A, et al: Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J 2014; 43: 1599–1609.
16.
Marin JM, Soriano JB, Carrizo SJ, Boldova A, Celli BR: Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med 2010; 182: 325–331.
17.
O’Donnell DE, Laveneziana P: Physiology and consequences of lung hyperinflation in COPD. Eur Respir Rev 2006; 15: 61–67.
18.
Owens R L, Malhotra A: Sleep-disordered breathing and COPD: the overlap syndrome. Respir Care 2010; 55: 1333–1346.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.